Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0026764 (multiple myeloma)
 36,148 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The levels of beta 2-microglobulin in urine and serum were determined in 39 patients with myelomatosis. In 25 patients the serum beta 2-microglobulin was elevated, and in seven of the patients with increased serum beta-microglobulin the urinary excretion of the protein was also increased. It was concluded that the increased urine beta-microglobulin indicates a renal tubular disorder.
 ...
PMID:Urinary excretion of beta 2-microglobulin in myeloma patients. 616 92

Sera from 244 patients with haematological malignancies were examined for beta 2-microglobulin (beta 2m) levels. There were 142 leukaemias, 32 malignant lymphomas, three immunoblastic lymphomas, two pseudolymphomas and 65 multiple myelomas. Culture supernatants from various established cell lines were also tested. The phenotype facilitating beta 2m shedding from the cell surface appeared to be independent of the specific IgG heavy chain allotypes; however, a myeloma group with normal serum beta 2m levels showed a significant association with the specific Gm allotypes. The determination of serum beta 2m levels can provide valuable information on the proliferative stage of the disorders, the effectiveness of chemotherapy, and be a diagnostic aid for blastic crisis in chronic myelocytic leukaemias, and for subtyping lymphoid malignancies.
 ...
PMID:Genetic and clinical studies of serum beta 2-microglobulin levels in haematological malignancies. 617 58

Serum beta 2-microglobulin (beta 2-m) is frequently increased in patients with myelomatosis. The possibility that it could provide a biochemical indicator of prognosis was tested in a group of 129 patients from 3 centres, all serum analyses being carried out in one laboratory by radioimmunoassay. A strong association between the pretreatment serum beta 2-m level and survival was demonstrated, the data for the 2 main subgroups being very similar. In further detailed analyses of 64 patients, serum beta 2-m proved to be a stronger indicator of prognosis than current "standard" clinical and laboratory data, including stage determined by the method of Durie and Salmon and the combination of haemoglobin level and blood urea. The association between serum beta 2-m and survival remained close after treatment as indicated by the findings at one year. The serum beta 2-m in myeloma reflects the tumour mass and also reduced glomerular filtration when renal failure supervenes. It is concluded that the serum beta 2-m is a powerful prognostic indicator in myelomatosis and of considerable value in the investigation of patients with the disease.
 ...
PMID:Evaluation of serum beta 2-microglobulin as a prognostic indicator in myelomatosis. 618 32

In 76 patients with clinically well defined multiple myeloma (median age at diagnosis: 68.5 years) serum-ferritin (SF) and beta 2-microglobulin (beta 2M) were measured by RIA-methods. 70 sex and age-matched healthy individuals served as controls. Both serum-ferritin (median: 343 micrograms/l vs. 193 micrograms/l; p less than 10(-7)) and beta 2M (median: 4.25 mg/l vs. 3.5 mg/l; p less than 0.01) showed a significant increase in myeloma patients compared to controls. Intercorrelation analysis revealed significant correlations between SF and tumour mass, serum-creatinine and beta 2M and between beta 2M and tumour mass, percentage of plasma cell infiltration in bone marrow, agglutinin titer, serum-creatinine, hemoglobin and age of the patients. Both tumour proteins might gain clinical importance particularly in those patients in which precise monitoring of disease is impossible either due to lack of paraprotein production or due to the particular paraprotein type. This seems to account for patients with light chain paraproteins, and furthermore for those patients with biclonal gammopathies or with IgE- and/or IgD-paraproteins.
 ...
PMID:[Serum ferritin and beta-2-microglobulin in multiple myeloma]. 618 72

A new human cell surface antigen (Hu Ly-m5) detected by a murine monoclonal antibody (E4.3) is described. The tissue distribution of the Hu Ly-m5 antigen is similar to the HLA antigens (with which it was initially confused) but it is not present on all bone marrow cells nor the U266 myeloma, and is expressed on the HLA-negative K562 cell line. Nevertheless, the Hu Ly-m5 antigen has some affinity for HLA molecules as the two entities cocap and the Hu Ly-m5 antigen copurifies with the HLA antigens on an anti-beta 2-microglobulin immunoabsorbent column; however, the antigen complexes did not withstand the procedures used for coprecipitation. Despite their similarities, the Hu Ly-m5 and HLA antigens are distinct molecular entities--Hu Ly-m5 consists of two bands of apparent molecular weight 69 and 60 K while HLA is comprised of the 43 and 12 K bands of the HLA heavy chain and beta 2-microglobulin, respectively. The function of the Hu Ly-m5 antigen is unknown, but no involvement in the cytotoxic T-lymphocyte response to influenza virus-infected cells could be demonstrated. The two properties described (apparent molecular weight and physical association with the HLA antigens) suggests that the Hu Ly-m5 antigen may be a viral-encoded protein.
 ...
PMID:Hu Ly-m5: a unique antigen physically associated with HLA molecules. 618 9

In 76 patients with clinically well-defined multiple myeloma (median age at diagnosis: 68.5 years), serum ferritin (SF) and beta 2-microglobulin (beta 2M) were measured by RIA methods. Seventy sex- and age-matched healthy individuals served as controls. Both serum ferritin (median: 343 vs 193 micrograms/liter; P less than 10(-7] and beta 2M (median: 4.25 vs 3.5 mg/liter) showed a significant increase (P less than 0.05) in myeloma patients compared to controls. Intercorrelation analysis revealed significant correlations between SF and tumor mass, serum creatinine, and beta 2M, and between beta 2M and tumor mass, percentage of plasma cell infiltration in bone marrow, agglutinine titers, serum creatinine, hemoglobin, and age of the patients. Both tumor proteins might gain clinical importance particularly in those patients in which precise monitoring of disease is impossible either due to lack of paraprotein production or due to the particular paraprotein type. This seems to account for patients with light chain paraproteins, and for those patients with biclonal gammopathies or with IgE and/or IgD paraproteins.
 ...
PMID:Serum ferritin and beta 2-microglobulin in patients with multiple myeloma. 619 21

Among 185 sera from 62 patients with multiple myeloma, two serum samples with high beta 2-microglobulin (beta 2m) binding activity (S beta 2m-BA) were investigated. The S beta 2m-BA was shown to be distinct from the monoclonal component and to be represented by autoantibody of the IgG class. These antibodies were specific for beta 2m. They formed macromolecular complexes with beta 2m, indicating that at least two distinct epitopes of beta 2m can be recognized by these antibody molecules. The association-dissociation constants and antigen binding capacities of these autoantibodies were compared with that of monoclonal or polyclonal heterologous antibodies.
 ...
PMID:Characterization of polyclonal autoantibodies specific for beta 2-microglobulin in multiple myeloma sera. 636 Apr 45

Serum beta 2-microglobulin (beta 2-M) measurements were carried out in 97 patients with monoclonal plasma cell disorders. Twenty-six (87%) of 30 patients with monoclonal gammopathy of undetermined significance (MGUS) had increased beta 2-M levels and serial follow-up in seven patients showed a progressive increase with time. Of the 63 patients with active myeloma, pretreatment serum beta 2-M values were available in 25 for correlation with pretreatment stage. Stage III beta 2-M levels were significantly higher than stages I and II (p less than 0.001). Four patients with smoldering myeloma had beta 2-M values similar to stage I disease. There was, therefore, excellent correlation between beta 2-M and myeloma tumor burden. Levels of beta 2-M decreased with response to chemotherapy induction and low levels in stable remission (plateau phase) were associated with unusually good prognosis. Median survival for stage III patients in stable remission with low serum beta 2-M was greater than 48 months. Conversely, at relapse very high beta 2-M levels were associated with a very fulminant and refractory course. Serum beta 2-M, therefore, appears to be an extremely useful marker in initial stratification and follow-up of myeloma patients.
 ...
PMID:Serum beta 2-microglobulin in the initial staging and subsequent monitoring of monoclonal plasma cell disorders. 636 46

The serum levels of beta 2-microglobulin (beta 2m), which is the light chain moiety of the HLA (-A, -B, -C) antigens, are increased in many of the haematological malignancies. In the lymphoproliferative disorders there is generally an association between serum beta 2m and estimates of tumour load. This relationship is especially close in myelomatosis, where serum beta 2m is a powerful prognostic indicator and can be used in stratification and monitoring. Increases in serum beta 2m are also frequent in the myeloproliferative disorders, notably in myelofibrosis, and in the myelodysplastic syndromes; particularly high levels are seen in chronic myelomonocytic leukaemia. In addition to suggested cellular sources of the beta 2m in these diseases--malignant lymphoid cells and cells of the monocyte-macrophage series--the possibility that T lymphocyte sub-sets could be important contributors to the increased beta 2m production is discussed.
 ...
PMID:Serum beta 2-microglobulin in lymphoproliferative and myeloproliferative diseases. 639 93

A monoclonal antibody, referred to as 38.13, was obtained by fusing murine myeloma cells with Lewis rat splenocytes sensitized with Daudi cells (human Burkitt lymphoma containing Epstein--Barr virus genome but lacking HLA-A, -B, and -C and beta 2-microglobulin molecules at the cell surface). 38.13 antibody was demonstrated to be a rat IgM. By complement-dependent microcytotoxicity and indirect immunofluorescence assays, 38.13 antibody was shown to react specifically with cells derived from Burkitt tumors, including both Epstein--Barr virus genome-carrying and Epstein--Barr virus-negative Burkitt lymphoma. By contrast, Epstein--Barr virus-containing lymphoblastoid cell lines derived from normal B lymphocytes were not recognized by 38.13 antibody. Fresh malignant cells from patients affected with various lymphoproliferative disorders were negative, except 4/8 having abdominal Burkitt-like lymphomas. Normal lymphocytes from peripheral blood, spleen, lymph node, tonsil, and bone marrow and mitogen (phytohemagglutinin, pokeweed mitogen, and concanavalin A)-activated blasts were also negative. Thus, 38.13 antibody apparently recognized a Burkitt-associated antigen that is not related to Epstein--Barr virus. The pattern of reactivity of 38.13 antibody with various Burkitt lymphoma cells appeared quite heterogenous and some Burkitt cells were consistently negative. 38.13 antibody thus defines a subset of Burkitt lymphomas.
 ...
PMID:Monoclonal antibody against a Burkitt lymphoma-associated antigen. 703 55


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>